Mortality and Technique Failure in Peritoneal Dialysis Patients Using Advanced Peritoneal Dialysis Solutions

被引:48
作者
Han, Seung Hyeok [1 ,2 ]
Ahn, Song Vogue [3 ]
Yun, Jee Young [4 ]
Tranaeus, Anders [5 ]
Han, Dae-Suk [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea
[2] Ilsan Hosp, Dept Internal Med, NHIC Med Ctr, Goyangshi, Gyeonggi Do, South Korea
[3] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul 120752, South Korea
[4] Baxter Healthcare Corp, Seoul, South Korea
[5] Baxter, Shanghai, Peoples R China
关键词
Biocompatibility; bicarbonate/lactate; low glucose degradation product (GDP); icodextrin; peritoneal dialysis; GLUCOSE-DEGRADATION-PRODUCTS; FLUID; BIOCOMPATIBILITY; ICODEXTRIN; EXPOSURE; IMPROVES; TRIAL;
D O I
10.1053/j.ajkd.2009.05.014
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite the theoretical benefits of biocompatible physiological-pH bicarbonate/lactate-buffered (B/L) peritoneal dialysis solution, there is only limited evidence supporting a superior clinical outcome associated with its use. Study Design: Observational study. Settings & Participants: 2,163 patients starting peritoneal dialysis therapy between July 2003 and December 2006 from 54 centers in Korea were enrolled. Predictors: B/L solution and icodextrin use. Outcomes: All-cause mortality and technique failure. Measurements: Patient outcomes were compared between patients prescribed B/L and conventional solutions by using propensity score and intention-to-treat analyses. Results: 542 patients initiated peritoneal dialysis therapy with B/L solution, and 1,621, with conventional solution. Fifteen patients prescribed B/L solution switched to conventional solution, and 386 of those initially using conventional solution switched to B/L solution during follow-up. Propensity score matching yielded 542 matched pairs of patients. In the matched cohort, there were no significant differences in age, diabetes, cardiovascular comorbidity, socioeconomic status, icodextrin use, or center experience between the 2 groups. All-cause deaths occurred in 52 (9.6%) patients in the B/L-solution group compared with 102 (18.9%) in the conventional-solution group (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.50 to 0.98; P = 0.04). In addition, icodextrin use was significantly associated with a reduced risk of death (HR, 0.40; 95% Cl, 0.28 to 0.58; P < 0.001). Thirty-three (6.1%) and 48 (8.9%) technique failures occurred in the B/L- and conventional-solution groups, respectively (HR, 0.91; 95% CI, 0.58 to 1.43; P = 0.7). The survival benefit of B/L solution persisted in the unmatched cohort (HR, 0.69; 95% CI, 0.52 to 0.93; P = 0.02). Limitations: Retrospective analysis, lack of laboratory data, and unknown indications for use of B/L solution. Conclusion: Use of a biocompatible B/L peritoneal dialysis solution with physiological pH is associated with improved survival compared with conventional solution. Large randomized clinical trials are warranted to confirm this finding. Am J Kidney Dis 54:711-720. (C) 2009 by the National Kidney Foundation, Inc.
引用
收藏
页码:711 / 720
页数:10
相关论文
共 33 条
[1]  
Barre DE, 1999, ADV PERIT D, V15, P12
[2]   Icodextrin improves the fluid status of peritoneal dialysis patients:: Results of a double-blind randomized controlled trial [J].
Davies, SJ ;
Woodrow, G ;
Donovan, K ;
Plum, J ;
Williams, P ;
Johansson, AC ;
Bosselmann, HP ;
Heimbürger, O ;
Simonsen, O ;
Davenport, A ;
Tranaeus, A ;
Divino, JC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09) :2338-2344
[3]   Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription [J].
Davies, SJ ;
Brown, EA ;
Frandsen, NE ;
Rodrigues, AS ;
Rodriguez-Carmona, A ;
Vychytil, A ;
MacNamara, E ;
Ekstrand, A ;
Tranaeus, A ;
Divino, JC .
KIDNEY INTERNATIONAL, 2005, 67 (04) :1609-1615
[4]  
FABBRINI P, 2006, NEPHROL DIAL TRANSPL, V21, pS8
[5]   Randomized controlled study of biocompatible peritoneal dialysis solutions: Effect on residual renal function [J].
Fan, S. L. S. ;
Pile, T. ;
Punzalan, S. ;
Raftery, M. J. ;
Yaqoob, M. M. .
KIDNEY INTERNATIONAL, 2008, 73 (02) :200-206
[6]   Metabolic and laboratory effects of icodextrin [J].
Gokal, R ;
Moberly, J ;
Lindholm, B ;
Mujais, S .
KIDNEY INTERNATIONAL, 2002, 62 :S62-S71
[7]   Mortality among hemodialysis patients in Europe, Japan, and the United States:: Case-mix effects [J].
Goodkin, DA ;
Young, EW ;
Kurokawa, K ;
Prütz, KG ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (05) :S16-S21
[8]   Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease - A propensity analysis [J].
Gum, PA ;
Thamilarasan, M ;
Watanabe, J ;
Blackstone, EH ;
Lauer, MS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (10) :1187-1194
[9]  
Ha H, 2002, PERITON DIALYSIS INT, V22, P171
[10]   Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis [J].
Higuchi, Chieko ;
Nishimura, Hideki ;
Sanaka, Tsutomu .
THERAPEUTIC APHERESIS AND DIALYSIS, 2006, 10 (04) :372-379